Skip to content
MMJ Gazette
  Friday 6 June 2025
  • About
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Authors
  • Home
  • News
  • CBD
  • Cannabis
  • Drugs
  • Marijuana
  • Tobacco
  • Law
Trending
May 29, 2025Ohio Ups Recreational Cannabis Purchase Quantities as Lawmaker Changes Loom May 23, 2025Texas House Passes Near-Total Ban on Hemp-Derived THC, Threatening $5.5 Billion Industry May 15, 2025California Governor Won’t Stop July Increase in Marijuana Excise Tax May 10, 2025Trulieve Workers Make Labor History with Arizona’s First Marijuana Cultivation Union Contract in 25 Years May 10, 2025Canopy Growth Faces Class-Action Lawsuit After Poor Earnings Report April 20, 2025Arizona Cannabis Sales Decline for Second Consecutive Year April 18, 2025Congressional Bills Aim to Provide Federal Marijuana Tax Relief and Limited Descheduling April 9, 2025Pennsylvania’s Plan for State-Run Marijuana Shops Hits a Federal Wall April 9, 2025Minnesota Judge Clears Path for Legal Weed Sales as Rulebook Gets Final Approval April 8, 2025Colorado Greenlights Doctor Prescriptions of Psilocybin Once FDA Gives the Nod, Virginia Says Not Yet
MMJ Gazette
MMJ Gazette
  • About
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Authors
MMJ Gazette
  Cannabis  Congress Fails to Deliver Marijuana Banking Reforms, Leaving Industry in Limbo
CannabisNews

Congress Fails to Deliver Marijuana Banking Reforms, Leaving Industry in Limbo

Lars BeckersLars Beckers—December 19, 20240
FacebookTwitterPinterestLinkedInTumblrRedditVKWhatsAppEmail

The 118th Congress has officially concluded its session without passing protections for marijuana banking, dashing hopes for legislative progress in one of the fastest-growing industries in the U.S. Despite bipartisan calls for reform, lawmakers left the $32 billion state-regulated cannabis sector without much-needed federal support.

Banking Woes Weigh on Cannabis Businesses

For years, cannabis advocates have lobbied for federal protections that would allow financial institutions to serve marijuana-related businesses without fear of penalties. While some banks cautiously engage with the industry, major players in the financial sector remain on the sidelines due to marijuana’s status as a Schedule I controlled substance.

This reluctance forces cannabis businesses to operate primarily in cash, increasing risks of theft and financial mismanagement. Industry leaders argue that the lack of access to reliable banking services not only stifles growth but also hampers efforts to build a transparent and regulated market. The absence of these protections also creates a significant hurdle for tax compliance, further burdening legal operators.

The Spending Bill and Its Implications

The recently unveiled spending bill aimed at avoiding a government shutdown included funding for disaster relief and farm aid but conspicuously excluded any measures to address marijuana banking. Advocates had hoped for provisions from the SAFE Banking Act, which would grant legal cannabis businesses access to the same financial services as other industries.

Democratic Majority Leader Chuck Schumer pointed fingers at Republican leadership, accusing them of blocking cannabis banking reforms. This sentiment echoes a similar scenario in 2021 when a last-minute push to attach banking protections to a defense bill also fell short. Critics argue that political gridlock and conflicting priorities continue to undermine progress on marijuana reform.

Frustration Among Industry Stakeholders

The cannabis community has expressed dismay over Congress’s inaction. David Culver, senior vice president for public affairs at the U.S. Cannabis Council, minced no words in his criticism, labeling the legislative session a disappointment. “This was a missed opportunity to bring safety and stability to an industry serving millions of Americans,” Culver said in a statement.

Some stakeholders remain cautiously optimistic about the future. The impending reclassification of marijuana to a Schedule III substance could ease some federal restrictions, and advocates hope that political shifts in the White House may open new doors. With Donald Trump returning to office in 2024, the cannabis sector anticipates alignment between presidential support and congressional action.

Challenges on the Road to Federal Legalization

The cannabis industry faces hurdles beyond banking. Here are some ongoing issues that demand attention:

  • Taxation: Cannabis businesses are subject to Section 280E of the IRS tax code, which prohibits them from deducting most business expenses, leading to disproportionately high tax rates.
  • Licensing Disparities: States vary widely in their licensing processes, creating a patchwork of regulations that complicate multi-state operations.
  • Public Perception: While public support for marijuana legalization is growing, stigma and misinformation still influence policy debates.

Efforts to address these challenges hinge on federal action, which remains elusive.

Issue Current Impact Potential Reform Benefit
Banking Access High operational risks, reliance on cash Safer, more transparent transactions
Tax Code (280E) Overburdened businesses, limited profitability Competitive tax environment
Licensing Inequities Barriers for small operators More equitable market opportunities
Federal Scheduling Hinders medical research and interstate commerce Unified regulatory framework

Looking Ahead to 2024 and Beyond

The cannabis industry’s frustration is palpable, but so is its resilience. Industry insiders are pinning their hopes on the 2024 election cycle to bring fresh momentum for reform. With a supportive administration and bipartisan backing for certain marijuana initiatives, stakeholders believe that progress is not a matter of “if” but “when.”

In the meantime, the industry continues to adapt, finding innovative ways to navigate financial constraints and regulatory challenges. While the road to federal legalization remains bumpy, the cannabis sector shows no signs of slowing down.

FacebookTwitterPinterestLinkedInTumblrRedditVKWhatsAppEmail

Lars Beckers

Lars Beckers is a distinguished senior content writer at MMJ Gazette, bringing a wealth of experience and expertise to the realm of medical marijuana and cannabis-related content. With a deep understanding of the industry and a passion for sharing knowledge, Lars's articles offer readers comprehensive insights and engaging narratives in the dynamic world of cannabis. Known for his meticulous research, clarity of expression, and commitment to delivering high-quality content, Lars brings a seasoned perspective to his work, educating and informing audiences on the latest trends and developments in the field.

Cannabis Brands Innovate Licensing Strategies to Enter New Markets
Weedmaps Shares Jump as Co-Founders Eye Privatization
Related posts
  • Related posts
  • More from author
Marijuana

Ohio Ups Recreational Cannabis Purchase Quantities as Lawmaker Changes Loom

May 29, 20250
Cannabis

Texas House Passes Near-Total Ban on Hemp-Derived THC, Threatening $5.5 Billion Industry

May 23, 20250
News

California Governor Won’t Stop July Increase in Marijuana Excise Tax

May 15, 20250
Load more
Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SEARCH
PROMOTIONS
RECENT POSTS
  • Ohio Ups Recreational Cannabis Purchase Quantities as Lawmaker Changes Loom
  • Texas House Passes Near-Total Ban on Hemp-Derived THC, Threatening $5.5 Billion Industry
  • California Governor Won’t Stop July Increase in Marijuana Excise Tax
  • Trulieve Workers Make Labor History with Arizona’s First Marijuana Cultivation Union Contract in 25 Years
  • Canopy Growth Faces Class-Action Lawsuit After Poor Earnings Report
  • Arizona Cannabis Sales Decline for Second Consecutive Year
  • Congressional Bills Aim to Provide Federal Marijuana Tax Relief and Limited Descheduling
  • Pennsylvania’s Plan for State-Run Marijuana Shops Hits a Federal Wall
  • Minnesota Judge Clears Path for Legal Weed Sales as Rulebook Gets Final Approval
  • Colorado Greenlights Doctor Prescriptions of Psilocybin Once FDA Gives the Nod, Virginia Says Not Yet
    © MMJ Gazette. 2024
    • About
    • Contact Us
    • Privacy Policy
    • Terms and Conditions
    • Authors